GAP President on Donanemab Trial Results: Alzheimer’s Patients and Their Doctors May Have Another Disease-Modifying Therapy to Address this Disease

WASHINGTON, DC, May 3, 2023 — Following the announcement of Eli Lilly’s Phase 3 results on a study evaluating donanemab for the treatment of Alzheimer’s disease, Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer said, “Today’s announcement is good news. After waiting nearly 20 years for a new treatment for Alzheimer’s, Alzheimer’s patients and their doctors are on the cusp of having another disease-modifying therapy to treat their condition.  Millions of people with Alzheimer’s and their families have real hope that they will have a brighter future fighting this disease.”

Lilly announced Wednesday morning that trial participants that received the drug showed a significant reduction in amyloid plaque (a protein associated with Alzheimer’s), a slowing of cognitive decline by 35%, and slowing of functional decline by 40% over 18 months.

“We congratulate Eli Lilly for continuing the hard research over the last couple of decades to arrive at these positive results,” Dwyer added. “Likewise, we are grateful for the many clinical study volunteers who joined the fight against Alzheimer’s by participating in these important research studies.  Finally, we encourage the FDA to review this much-needed therapy and expeditiously determine whether it is safe and effective.”


For immediate release:


About GAP Foundation

The Global Alzheimer’s Platform Foundation® (GAP) is a patient-centered nonprofit organization dedicated to accelerating the delivery of innovative therapies for neurological disorders by reducing the duration and cost of clinical trials. Over 100 research centers around the world are part of the growing GAP Network (GAP-Net). 

To top